An observational study in Kidney Failure, Chronic and Quality of Life, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-17.
Sponsored by Assiut University · Observational
Among 17 studies in Kidney Failure, Chronic by Assiut University — 8 open to participants now, 8 under way, none of them phase 3. Kidney Failure, Chronic · Assiut University.
Among the 17 studies in Kidney Failure, Chronic by Assiut University, this one is the 3rd largest by planned enrollment of the 13 observational ones, is one of 5 that started in 2026, is one of 6 observational ones, and was the 16th registered.
2,108 studies on the registry are indexed under Kidney Failure, Chronic; 273 are open to participants now.
This study's planned enrollment of 130 is close to the median of 120 across 442 observational studies indexed under Kidney Failure, Chronic.
Browse Kidney Failure, Chronic studies →8 of the 17 studies in Kidney Failure, Chronic by Assiut University are open now, in 1 country. Each count lists the studies.
Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →17 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 5 started in 2026.
Median enrollment 81 across the 4 interventional studies, 100 across the 13 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
4 of the studies in Kidney Failure, Chronic by Assiut University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07803237Assiut UniversityPredictors of Rapid CKD Progression | 2027-09-01 |
| NCT07821788Assiut UniversityTwice vs Thrice Weekly Hemodialysis: Clinical Outcomes and Quality of Life | 2027-09-10 |
| NCT07820150Assiut UniversityHyperparathyroidism and Dialysis Adequacy in Hemodialysis Patients | 2027-09-10 |
| NCT07817953Assiut UniversityAVF Awareness Among Advanced CKD Patients | 2027-09-10 |
Among the 17 studies in Kidney Failure, Chronic by Assiut University, from their registry updates:
This prospective cohort study aims to compare clinical outcomes and health-related quality of life between adults receiving established twice-weekly versus thrice-weekly maintenance hemodialysis at Assiut University Hospitals.
Thrice-weekly maintenance hemodialysis is the conventional schedule. Twice-weekly hemodialysis is used selectively in patients with residual kidney function. Local prospective comparative data in Egypt are limited.
This observational study will include adults with end-stage kidney disease receiving established twice-weekly or thrice-weekly in-center maintenance hemodialysis. Patients will be followed according to their prescribed schedule without research-driven changes. Health-related quality of life will be assessed using the Arabic KDQOL-36 at baseline, 3 months, and 6 months. Clinical outcomes including adequacy, residual kidney function, hospitalization, and mortality will be recorded.
Adults with end-stage kidney disease receiving maintenance in-center hemodialysis at Assiut University Hospitals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults receiving established twice-weekly maintenance hemodialysis.
Adults receiving established thrice-weekly maintenance hemodialysis.
Health-related quality of life score
Mean total score of the Arabic Kidney Disease Quality of Life-36 (KDQOL-36) questionnaire. The KDQOL-36 score ranges from 0 to 100; higher scores indicate better health-related quality of life.
Time frame: At baseline, 3 months, and 6 months
Dialysis adequacy
Mean single-pool Kt/V (for thrice-weekly) or weekly Kt/V incorporating residual kidney clearance (for twice-weekly).
Time frame: Up to 6 months
Residual urine output
Mean daily urine volume (mL/day) in patients with residual kidney function.
Time frame: Up to 6 months
Hospitalization rate
Proportion of patients requiring hospital admission during follow-up.
Time frame: Up to 6 months
Interdialytic weight gain
Mean interdialytic weight gain (kg).
Time frame: Up to 6 months
Mortality
Proportion of patients who die during the follow-up period.
Time frame: Up to 6 months
No study locations are listed for this record.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.